Dyne Therapeutics (DYN) Operating Leases (2021 - 2026)
Dyne Therapeutics (DYN) posted quarterly Operating Leases of $14.5 million for Q2 2026, down 15.97% year-over-year from $17.3 million in Q2 2025, and up 1.64% quarter-over-quarter from $14.3 million in Q1 2026.
Dyne Therapeutics (DYN) Operating Leases (2021 - 2026) Analysis & Trends
Dyne Therapeutics (DYN) has reported Operating Leases for 6 consecutive years, with $14.5 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Operating Leases fell 15.97% year-over-year to $14.5 million; the TTM figure through Jun 2026 stood at $14.5 million (down 15.97% YoY), while the FY2025 annual figure was $15.3 million, down 20.14% from the prior year.
- Operating Leases climbed to $14.5 million in Q2 2026 per DYN's latest filing, from $14.3 million in the prior quarter.
- Across five years, Operating Leases topped out at $28.1 million in Q1 2022 and bottomed at $14.3 million in Q1 2026.
- Historically, Operating Leases has averaged $21.2 million across 5 years, with a median of $21.4 million in 2024.
- Annual changes were most pronounced in 2022 — Operating Leases jumped 6685.36% — and 2026, when it declined 21.67%.
- Dyne Therapeutics' Operating Leases stood at $25.9 million in 2022, then declined by 12.28% to $22.7 million in 2023, then fell by 15.67% to $19.1 million in 2024, then decreased by 20.14% to $15.3 million in 2025, then retreated by 5.09% to $14.5 million in 2026.
- Business Quant data shows DYN's Operating Leases at $14.5 million in Q2 2026, $14.3 million in Q1 2026, and $15.3 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Dyne Therapeutics | 4.26 Bn | 4.26 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.51 Mn |
| Mar 31, 2026 | 14.27 Mn |
| Dec 31, 2025 | 15.28 Mn |
| Sep 30, 2025 | 16.28 Mn |
| Jun 30, 2025 | 17.26 Mn |
| Mar 31, 2025 | 18.22 Mn |
| Dec 31, 2024 | 19.14 Mn |
| Sep 30, 2024 | 20.04 Mn |
| Jun 30, 2024 | 20.94 Mn |
| Mar 31, 2024 | 21.86 Mn |
| Dec 31, 2023 | 22.70 Mn |
| Sep 30, 2023 | 23.51 Mn |
| Jun 30, 2023 | 24.32 Mn |
| Mar 31, 2023 | 25.12 Mn |
| Dec 31, 2022 | 25.87 Mn |
| Sep 30, 2022 | 26.61 Mn |
| Jun 30, 2022 | 27.35 Mn |
| Mar 31, 2022 | 28.07 Mn |
| Dec 31, 2021 | 28.74 Mn |
| Sep 30, 2021 | 29.41 Mn |